Objective
Europe has an ageing demographic, 25% of the population over 40 years old suffer from eye disesase. As an example, 5% of the diagnosed disease are categorised as Age-related Macular Degeneration (hereafter AMD). This disease can be treated, if diagnosed early.
The problem:
A number of severe diseases, such as AMD, can be diagnosed by scanning and analyzing the retina, however due to microscopic movement of the eye, only a small part of the retina can be “photographed” as the current technology is too slow to capture a clear image.
The method used to diagnose eye diseases is called “Optical Coherence Tomography” (hereafter OCT) 2D imaging, and is usually performed by specialised eye doctors (ophthalmologists). To enable earlier diagnosis, screening for eye diseases such as AMD are increasingly being done by opticians, but due to the complexity of the eye, and the quality of the 2D images, this leads to many false-positives.
Despite the clear benefit of earlier screening, the many false-positive resulys found by opticians are a burden on ophthalmologist and are taking up time and resources.
The solution:
OCTLIGHT has developed a patented specialized light source module, that enables OCT “eye scanner” devices to scan the eye 10x faster than the technology presently used, giving them the ablity to do clear wide field 3D image scans of the eye.
The wide field 3D images make it easier for ophthalmologists to detect eye diseases, but just as significant, the high quality of the data (image) allows for the use of Machine Learning for diagnosing eye diseases.
This means that OCTLIGHTs technology enables better screening, which can be combined with Machine Learning to enable better and more reliable diagnosis even if performed by opticians. This should reduce the many false-positives found, enabling efficient and cost-saving diagnosis and treatment.
Fields of science
- medical and health sciencesclinical medicineophthalmologyglaucoma
- medical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosis
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health sciencesclinical medicineophthalmologyretinopathy
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
2800 LYNGBY
Denmark
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.